Home
About
FAQ
History (19)
An unfortunate preventable complication: duplicate publication.
Support for a nicotine reduction policy among participants enrolled in a 20-week trial of very low nicotine content cigarettes.
Genomewide screen for pulmonary function in 200 families ascertained for asthma.
Predictors of Retest Effects in a Longitudinal Study of Cognitive Aging in a Diverse Community-Based Sample.
Selecting disease-modifying medications in 5q spinal muscular atrophy.
See All 19 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Selecting disease-modifying medications in 5q spinal muscular atrophy.
Cartwright MS, Upadhya S. Selecting disease-modifying medications in 5q spinal muscular atrophy. Muscle Nerve. 2021 Oct; 64(4):404-412.
View in:
PubMed
subject areas
Animals
Azo Compounds
Biological Products
Humans
Muscular Atrophy, Spinal
Neuromuscular Agents
Oligonucleotides
Oligonucleotides, Antisense
Pyrimidines
Recombinant Fusion Proteins
Treatment Outcome
authors with profiles
Michael S. Cartwright MD